Cargando…

Increasing Options for First-Line Therapy in Primary FSGS?

Detalles Bibliográficos
Autor principal:	Lafayette, Richard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308904/ https://www.ncbi.nlm.nih.gov/pubmed/30596161 http://dx.doi.org/10.1016/j.ekir.2018.10.016

Ejemplares similares

Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience
por: Vallianou, Kalliopi, et al.
Publicado: (2021)

Therapeutic approach to FSGS in children
por: Gipson, Debbie S., et al.
Publicado: (2007)

Changing the Paradigm for the Treatment and Development of New Therapies for FSGS
por: Spino, Cathie, et al.
Publicado: (2016)

Has the circulating permeability factor in primary FSGS been found?
por: Jefferson, J. Ashley, et al.
Publicado: (2013)

FSGS: Diagnosis and Diagnostic Work-Up
por: Sprangers, Ben, et al.
Publicado: (2016)

The Impact of Histologic Variants on FSGS Outcomes
por: Meliambro, Kristin, et al.
Publicado: (2014)

Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review
por: Miao, Jing, et al.
Publicado: (2023)

Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor
por: Savin, Virginia J., et al.
Publicado: (2017)

FSGS Recurrence in Adults after Renal Transplantation
por: Rudnicki, Michael
Publicado: (2016)

Rituximab in the treatment of primary FSGS: time for its use in routine clinical practice?
por: Morris, Adam D, et al.
Publicado: (2023)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies
por: Lafayette, Richard A., et al.
Publicado: (2023)

Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line
por: Roth, Gael S., et al.
Publicado: (2020)

Therapeutic trials in adult FSGS: lessons learned and the road forward
por: De Vriese, An S., et al.
Publicado: (2021)

Recurrence and Treatment after Renal Transplantation in Children with FSGS
por: Kang, Hee Gyung, et al.
Publicado: (2016)

LAMA2 and LOXL4 are candidate FSGS genes
por: Vijayan, Poornima, et al.
Publicado: (2021)

Comparative proteomic analysis of children FSGS FFPE tissues
por: Ni, Jiajia, et al.
Publicado: (2022)

FSGS and COVID-19 in Non–African American Patients
por: Medina, Elba, et al.
Publicado: (2023)

Options for first line therapy of Hodgkin lymphoma
por: Longley, Jemma, et al.
Publicado: (2019)

Pemphigus vulgaris and focal segmental glomerulosclerosis (FSGS): First reported case and a review of the literature
por: Sadeghzadeh‐Bazargan, Afsaneh, et al.
Publicado: (2023)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

A Novel TRPC6 Mutation That Causes Childhood FSGS
por: Heeringa, Saskia F., et al.
Publicado: (2009)

Compound effects of aging and experimental FSGS on glomerular epithelial cells
por: Schneider, Remington R.S, et al.
Publicado: (2017)

Role of Sphingolipid Signaling in Glomerular Diseases: Focus on DKD and FSGS
por: Mitrofanova, Alla, et al.
Publicado: (2020)

Clinical and Pathological Heterogeneity in FSGS due to INF2 Mutations
por: Morales-Alvarez, Martha Catalina, et al.
Publicado: (2022)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing
por: Brown, Elizabeth J., et al.
Publicado: (2014)

IgM and C3 Deposition in Primary Focal Segmental Glomerulosclerosis (FSGS): A Clinical and Histopathological Spectrum
por: Amer, Faizan, et al.
Publicado: (2023)

Podocyte RNA sequencing reveals Wnt- and ECM-associated genes as central in FSGS
por: Bukosza, Eva Nora, et al.
Publicado: (2020)

Characterization of a Trpc6 Transgenic Mouse Associated with Early Onset FSGS
por: Canales, Cesar P., et al.
Publicado: (2014)

Stem cell therapy: a novel treatment option for cerebral malaria?
por: Wang, Wei, et al.
Publicado: (2015)

Genetic mutational testing of Chinese children with familial hematuria with biopsy-proven FSGS
por: Li, Yongzhen, et al.
Publicado: (2018)

Effects of FSGS-associated mutations on the stability and function of myosin-1 in fission yeast
por: Bi, Jing, et al.
Publicado: (2015)

The protective effect of Phellinus linteus decoction on podocyte injury in the kidney of FSGS rats
por: Wan, Feng, et al.
Publicado: (2019)

Treatment of post-transplant recurrent FSGS in children using plasmapheresis and augmentation of immunosuppression
por: Restrepo, Jaime M., et al.
Publicado: (2022)

CUBN gene mutations may cause focal segmental glomerulosclerosis (FSGS) in children
por: Yang, Jing, et al.
Publicado: (2022)

Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors
por: Rashmi, Priyanka, et al.
Publicado: (2023)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
por: Lee, Jiwon M., et al.
Publicado: (2019)

Tongue as a first-line immune organ?
por: Wu, Jane Y.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ds156or1rip8qop7upbq0bb3c